Selective Serotonin Reuptake Inhibitors: all 1,366 studies that test it

Page 8 of 14. Open to participants first (105), then studies with results posted, then the rest; newest registration first within each.

• Add-on to Cognitive, Event-Related Potentials (ERP) and Electroencephalogram (EEG) Asymmetry in Affective DisordersWithdrawnNCT03278938Phase 4
• Psycho-biological Substrates of Therapeutic Benefit of Thermal Cure on Generalized Anxiety DisordersCompletedNCT03277339Phase 4
• A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 FlutemetamolTerminatedNCT03274817Phase 1
• Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial InfarctionCompletedNCT03274752Phase 2
• Oral Olanzapine Versus Haloperidol or DiazepamTerminatedNCT03246620Phase 4
• "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"CompletedNCT03219710Phase 3
• Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological CharacteristicsStatus unknownNCT03219008Phase 4
• Trazodone in Painful Diabetic NeuropathyCompletedNCT03202979Phase 2
• Cognitive Dysfunction in MDD PatientsStatus unknownNCT03187093Phase 4
• Serotonin and Motor PlasticityStatus unknownNCT03162185Phase 4
• Hot Flash as a Marker of Cardiovascular Risk in Recent Postmenopause: Effects of Non-hormonal TreatmentsCompletedNCT03149419Phase 4
• A Diagnosis and Treatment Optimization Study of Depression Based on the Neurological Mechanism of Reward SystemStatus unknownNCT03148522Not applicable
• Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety DisordersStatus unknownNCT03122158Phase 4
• RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic ChemotherapyCompletedNCT03118986Phase 2
• Escitalopram for Agitation in Alzheimer's DiseaseActive, not recruitingNCT03108846Phase 3
• Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of AgeCompletedNCT03108625Phase 3
• Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer PatientsCompletedNCT03079219Phase 3
• Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline.CompletedNCT03068429Phase 4
• Impact of Genetic Polymorphism on Drug-Drug Interactions Involving CYP2D6CompletedNCT03054220Not applicable
• Establishment of Cessation Therapy by Clinical Trials for Subjects With Betel-quid Dependence and Oral Pre-cancerTerminatedNCT03010761Phase 2
• Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of CINStatus unknownNCT02970643Not applicable
• CAMH - McMaster Collaborative Care Initiative For Mental Health Risk Factors In DementiaCompletedNCT02955719Not applicable
• Trazodone Dose Tolerance and APAP AdherenceSuspendedNCT02945644Phase 1
• An Insulin Sensitivity Study in Healthy SubjectsCompletedNCT02922426Phase 1
• Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive DisorderCompletedNCT02919501Phase 2
• Measurement-based Care for Depression in Resource-Poor SettingsCompletedNCT02916238Phase 4
• Sertraline in Addition to Standard of Care Treatment for CoccidioidomycosisWithdrawnNCT02908334Phase 2
• Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AMLCompletedNCT02891278Phase 1
• Treatment Outcome in Major Depressive DisorderCompletedNCT02869035Phase 1
• Cortical Ischemic Stroke and SerotoninStatus unknownNCT02865642Phase 2
• Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD StudyCompletedNCT02861859Phase 3
• Long Term Treatment of Panic Disorder With Clonazepam or ParoxetineCompletedNCT02852577Phase 4
• Vortioxetine for the Treatment of Major Depression and Co-morbidities After Traumatic Brain Injury (TBI)WithdrawnNCT02845349Phase 3
• PPI's and SSRI's Therapy for the Management of NCCPTerminatedNCT02825342Phase 4
• Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With AnxietyCompletedNCT02818751Not applicable
• A Phase 1 Safety Study in Adults With SchizophreniaCompletedNCT02804568Phase 1
• PK Study of Multi-dose Trazodone Hydrochloride Prolonged-released Tablets in Healthy ChineseCompletedNCT02785614Phase 1
• Serotonin Selective Reuptake Inhibitor (SSRI) Effects on Cerebral Connectivity in Acute Ischemic StrokeCompletedNCT02767999Phase 4
• Enhancement of Learning Associated Neural Plasticity by Selective Serotonin Reuptake InhibitorsStatus unknownNCT02753738Phase 4
• The Staged Treatment in Early Psychosis StudyCompletedNCT02751632Phase 3
• The Study of the Pathogenesis and Cognitive Behavioral Group Therapy in Obsessive-Compulsive DisorderCompletedNCT02739061Not applicable
• Hierarchical Treatment Based on Somatization Symptom ChecklistStatus unknownNCT02723903Phase 1/2
• Molecular Mechanisms of Antipsychotic-induced Insulin ResistanceCompletedNCT02708394Early Phase 1
• Obstructive Sleep Apnea and Arousal Threshold in Patients With Post-traumatic Stress DisorderWithdrawnNCT02699138Early Phase 1
• Efficacy of Fluoxetine - a Trial in StrokeCompletedNCT02683213Phase 3
• Lofexidine Pharmacokinetics in the Presence of Paroxetine in Healthy VolunteersCompletedNCT02681198Phase 1
• Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut EpilepsyCompletedNCT02655198Phase 2
• Study to Evaluate The Effect Of Sertraline on the Cardiac Repolarization in Healthy SubjectsCompletedNCT02651623Phase 1
• The Role of miR-30 Family Dysregulation in Response to Antipsychotic TreatmentStatus unknownNCT02650102Phase 1/2
• A Randomized Controlled Trial of Sertraline in Paroxysmal Arterial HypertensionStatus unknownNCT02641652Phase 4
• Vortioxetine for MDD, Cognition, and Systemic Inflammatory BiomarkersWithdrawnNCT02637466Phase 4
• The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma PatientsStatus unknownNCT02623231Phase 2/3
• Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in GhanaCompletedNCT02593734Phase 4
• Efficacy of Fluoxetine Against Seizure-induced Central ApneasCompletedNCT02569970Phase 3
• Efficacy of Nepeta Menthoides Extract on Anxiety of Patients With Depression: a Double-blind Randomized Controlled Clinical TrialCompletedNCT02565316Phase 2/3
• Does Adding Oral Contraceptives to Fluoxetine Improve the Management of Premenstrual Syndrome?Status unknownNCT02562053Phase 3
• Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk YouthCompletedNCT02553161Not applicable
• Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive EpisodeTerminatedNCT02532660Phase 3
• Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in Severe Premenstrual SyndromeStatus unknownNCT02488538Phase 3
• Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mgCompletedNCT02485041Phase 1
• Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 50mgCompletedNCT02485028Phase 1
• The Effect of Patient and Investigator Expectation on the Efficacy of Escitalopram in the Treatment DepressionCompletedNCT02480400Not applicable
• Acute Myocardial Necrosis and Depression: Antiplatelet Effect of Reuptake Inhibition of SerotoninTerminatedNCT02463110Phase 4
• Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery DiseaseWithdrawnNCT02454426Early Phase 1
• Sertraline in Treatment of Low-Risk Myelodysplastic SyndromeTerminatedNCT02452983Phase 1
• Newer Antidepressants in Combination With Pregabalin for Fibromyalgia SyndromeCompletedNCT02451475Phase 1/2
• Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin ExtractionCompletedNCT02447835Phase 1
• The Effect of Fluvoxamine on Polysonogram in Depressed Patients With InsomniaStatus unknownNCT02442713Not applicable
• 5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset SchizophreniaCompletedNCT02435654Phase 4
• Dienogest Versus Luteal Phase Fluoxetine in the Management of Premenstrual SyndromeStatus unknownNCT02427334Phase 3
• The Routine Use of SSRI's at the Initiation of End-stage Renal Disease Treatment (RoSIE)TerminatedNCT02407821Phase 2
• A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic ChemotherapyStatus unknownNCT02400866Phase 2
• A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic DisorderCompletedNCT02395510Phase 4
• Pharmacokinetic Properties of Vortioxetine in Healthy Young Chinese Men and WomenCompletedNCT02386488Phase 1
• Effect of Serotonin and Levodopa in Ischemic StrokeCompletedNCT02386475Phase 4
• IM Olanzapine Versus Haloperidol or MidazolamTerminatedNCT02380118Phase 4
• Pharmacovigilance in Gerontopsychiatric PatientsTerminatedNCT02374567Phase 3
• Adjunctive Vortioxetine in SchizophreniaActive, not recruitingNCT02357797Phase 4
• Trial of Sertraline Versus Cognitive Behaviour Therapy for Generalised AnxietyTerminatedNCT02347033Phase 4
• Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking VortioxetineCompletedNCT02332954Phase 4
• Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic PatientsCompletedNCT02307396Phase 4
• Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety DisorderStatus unknownNCT02294305Phase 4
• Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus PaclitaxelStatus unknownNCT02290470Phase 2
• Olanzapine Versus Lithium in the Treatment of Acute Depression in Patients With Bipolar II or Bipolar Not Otherwise Specified(OL Study)CompletedNCT02287259Phase 4
• The Gut Microbiota in Obsessive-Compulsive DisorderCompletedNCT02285699Not applicable
• Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive DisorderCompletedNCT02279966Phase 3
• Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive DisorderCompletedNCT02279953Phase 3
• Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive DisorderCompletedNCT02272517Phase 3
• A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A)CompletedNCT02269540Early Phase 1
• Integral Assessment in Unipolar DepressionStatus unknownNCT02268487Phase 4
• Study to Investigate the Effect of Paroxetine Mediated CYP2D6 Inhibition on the Pharmacokinetics of Tamsulosin in Healthy Male VolunteersCompletedNCT02264184Phase 1
• Randomized, Double Blind, Efficacy Study of Escitalopram in ENT Cancer Patients Suffering From Emotional DistressCompletedNCT02246244Phase 3
• Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 GeneStatus unknownNCT02237937Phase 4
• The Effect of a Selective Serotonin Reuptake Inhibitor on Gait, Balance, and Bone Metabolism in Older AdultsCompletedNCT02228005Phase 4
• Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive DisorderCompletedNCT02194075Phase 4
• The Measurement-based Care in Patients With Depressive Disorder: A Randomized Controlled TrialCompletedNCT02191124Phase 4
• Effects and Consequences for Mother and Child From Treatment for DepressionTerminatedNCT02185547Phase 4
• Antidepressants and Bone Mineral DensityCompletedNCT02179268Phase 3
• A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy SubjectsCompletedNCT02174822Phase 1
• SSRI Study for Functional Dyspepsia (SS)CompletedNCT02153567Phase 3

← Selective Serotonin Reuptake Inhibitors overview